Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hV01 in advanced malignant solid tumors
NCT05914376Phase 1Active, not recruiting
- Sponsor
- Hangzhou ConVerd Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of CVD-1301.V01 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Hangzhou ConVerd Co., Ltd. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse events. Started Jul 2023; status: active, not recruiting.
02
Drugs
CVD-1301.V01
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT05914376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914376.